Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.53 |
| ▸ | ULK1 | O75385 | 2/20 | 0.52 |
| ▸ | MAPK3 | P27361 | 6/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911259 | 0.92 | LRRK2 (0.65) | LRRK2ULK1MAPK3CCNKCCNA2 | |
| SCHEMBL9911263 | 0.90 | LRRK2 (0.50) | LRRK2MAPK3CCNKCCNA2CDK2 | |
| SCHEMBL9911266 | 0.87 | LRRK2 (0.56) | LRRK2MAPK3EGFRINSRALK | |
| SCHEMBL9912361 | 0.86 | ROS1 (0.55) | LRRK2MAPK3EGFRALK | |
| SCHEMBL9911260 | 0.86 | LRRK2 (0.71) | LRRK2MAPK3CDK9EGFRINSR | |
| Hydrochloric Acid SCHEMBL1707360 | 0.85 | ROS1 (0.55) | LRRK2MAPK3EGFRALK | |
| SCHEMBL9911258 | 0.85 | MAPK3 (0.49) | LRRK2MAPK3CCNKCCNA2CDK2 | |
| SCHEMBL9911257 | 0.85 | LRRK2 (0.55) | LRRK2MAPK3CCNKCCNA2CDK2 | |
| SCHEMBL29574992 | 0.83 | ULK1 (0.53) | LRRK2ULK1MAPK3CCNKCCNA2 | |
| SCHEMBL17547470 | 0.83 | ULK1 (0.53) | LRRK2ULK1MAPK3CCNKCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | ZAP70, LCK, DPY30 | LRRK2 3072/4885ULK1 2633/4885MAPK3 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.